Epizyme (NASDAQ:EPZM) has been given a $26.00 price objective by equities research analysts at Oppenheimer in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 102.33% from the stock’s current price.
A number of other equities research analysts also recently weighed in on EPZM. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Royal Bank of Canada restated a “buy” rating and issued a $20.00 target price on shares of Epizyme in a research note on Friday, September 15th. Cann restated a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Jefferies Group assumed coverage on shares of Epizyme in a research note on Wednesday, September 20th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $22.67.
Shares of Epizyme (NASDAQ:EPZM) opened at $12.85 on Tuesday. Epizyme has a 52 week low of $9.30 and a 52 week high of $20.45.
In related news, Director David M. Mott purchased 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $91,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $16.81, for a total transaction of $252,150.00. Following the transaction, the insider now owns 23,123 shares in the company, valued at approximately $388,697.63. The disclosure for this sale can be found here. 25.20% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in EPZM. Point72 Asset Management L.P. bought a new stake in Epizyme during the 3rd quarter worth about $17,591,000. Palo Alto Investors LLC raised its holdings in Epizyme by 18.9% during the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after purchasing an additional 907,245 shares during the last quarter. State Street Corp raised its holdings in Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after purchasing an additional 658,727 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in Epizyme during the 2nd quarter worth about $9,726,000. Finally, Bain Capital Public Equity Management LLC bought a new stake in Epizyme during the 2nd quarter worth about $4,331,000. 85.28% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://sportsperspectives.com/2017/12/12/oppenheimer-analysts-give-epizyme-epzm-a-26-00-price-target.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.